Mouse Progranulin/PGRN Antibody

Detection of Mouse Progranulin/PGRN by Immunocytochemistry/Immunofluorescence

PGRN immunolabeling following ND-602.(A) Representative photomicrographs depicting PGRN immunolabeling in the dentate gyrus of the Tg2576 mouse brain following unilateral intracerebral administration of either LV-GFP, or LV-PGRN (ND-602). (B) The hippocampal density of PGRN immunolabeling was significantly elevated following ND-602 administration in both the ipsilateral and contralateral hemispheres. (C) PGRN protein expression (progranulin/ beta-actin gray values) in the hippocampus was detected by western blot assay. (D) Representative fluorescent photomicrographs depicting PGRN immunolabeling in the entorhinal cortex and frontal cortex following unilateral intracerebral administration of either LV-GFP, or LV-PGRN (ND-602). (E) The density of PGRN immunolabeling was significantly elevated following ND-602 administration in both hemispheres. By contrast, elevations in the (F) frontal cortex did not reach statistical significance. (G) Representative fluorescent photomicrograph depicting GFP (green) and NeuN (red) immunolabeling throughout the ipsilateral hippocampus following lentiviral delivery. The image is a tiled composite of multiple images obtained at 20X magnification. A closer view, (H) shows viral transduction of both NeuN-positive and–negative cells. Each bar represents the mean (± S.E.M.) (n = 8–10) optical density measured across 4 coronal sections. ** sig. diff. from GFP-treated controls, p < 0.001; * p < 0.05. ++ sig. diff. from contralateral hemisphere, p < 0.001. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28837568), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse Progranulin/PGRN by Immunocytochemistry/Immunofluorescence

PGRN immunolabeling following ND-602.(A) Representative photomicrographs depicting PGRN immunolabeling in the dentate gyrus of the Tg2576 mouse brain following unilateral intracerebral administration of either LV-GFP, or LV-PGRN (ND-602). (B) The hippocampal density of PGRN immunolabeling was significantly elevated following ND-602 administration in both the ipsilateral and contralateral hemispheres. (C) PGRN protein expression (progranulin/ beta-actin gray values) in the hippocampus was detected by western blot assay. (D) Representative fluorescent photomicrographs depicting PGRN immunolabeling in the entorhinal cortex and frontal cortex following unilateral intracerebral administration of either LV-GFP, or LV-PGRN (ND-602). (E) The density of PGRN immunolabeling was significantly elevated following ND-602 administration in both hemispheres. By contrast, elevations in the (F) frontal cortex did not reach statistical significance. (G) Representative fluorescent photomicrograph depicting GFP (green) and NeuN (red) immunolabeling throughout the ipsilateral hippocampus following lentiviral delivery. The image is a tiled composite of multiple images obtained at 20X magnification. A closer view, (H) shows viral transduction of both NeuN-positive and–negative cells. Each bar represents the mean (± S.E.M.) (n = 8–10) optical density measured across 4 coronal sections. ** sig. diff. from GFP-treated controls, p < 0.001; * p < 0.05. ++ sig. diff. from contralateral hemisphere, p < 0.001. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28837568), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse Progranulin/PGRN by Western Blot

PGRN immunolabeling following ND-602.(A) Representative photomicrographs depicting PGRN immunolabeling in the dentate gyrus of the Tg2576 mouse brain following unilateral intracerebral administration of either LV-GFP, or LV-PGRN (ND-602). (B) The hippocampal density of PGRN immunolabeling was significantly elevated following ND-602 administration in both the ipsilateral and contralateral hemispheres. (C) PGRN protein expression (progranulin/ beta-actin gray values) in the hippocampus was detected by western blot assay. (D) Representative fluorescent photomicrographs depicting PGRN immunolabeling in the entorhinal cortex and frontal cortex following unilateral intracerebral administration of either LV-GFP, or LV-PGRN (ND-602). (E) The density of PGRN immunolabeling was significantly elevated following ND-602 administration in both hemispheres. By contrast, elevations in the (F) frontal cortex did not reach statistical significance. (G) Representative fluorescent photomicrograph depicting GFP (green) and NeuN (red) immunolabeling throughout the ipsilateral hippocampus following lentiviral delivery. The image is a tiled composite of multiple images obtained at 20X magnification. A closer view, (H) shows viral transduction of both NeuN-positive and–negative cells. Each bar represents the mean (± S.E.M.) (n = 8–10) optical density measured across 4 coronal sections. ** sig. diff. from GFP-treated controls, p < 0.001; * p < 0.05. ++ sig. diff. from contralateral hemisphere, p < 0.001. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28837568), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human Mouse Progranulin/PGRN Antibody by Western Blot

PSAP and PGRN levels are decreased in cingulate cortex tissue of schizophrenia patients. (A) Representative immunoblots of PSAP, PGRN, and beta-actin in cingulate cortex tissue from subjects of healthy control (Ctrl), schizophrenia (SCZ), bipolar disorder (BP), and major depressive disorder (MDD). Upper panel, illustration of cingulate cortex in human brain. (B,C) Bar graphs presenting quantification of the ratio of protein levels of PSAP/ beta-actin (B) and PGRN/ beta-actin (C). (D,E) Scatter plots showing the Pearson’s correlation analysis of PSAP and lifetime quantity of fluphenazine or equivalent (FLU) in schizophrenia (D) and bipolar disorder group (E), respectively. Each dot represents one patient of SCZ (blue) or BP (magenta). (F,G) Scatter plots showing the Pearson’s correlation analysis of PGRN and FLU in schizophrenia (F) and bipolar disorder group (G), respectively. One-way ANOVA with Sidak’s post hoc test. N = 11–12 samples in each group. Data are presented as mean ± S.E.M. * p ˂ 0.05 compared to Ctrl. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/36233357), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse Mouse Progranulin/PGRN Antibody by Immunohistochemistry

Conditional deletion of neuronal PSAP in the cingulate cortex causes downregulation of neuronal PGRN. (A) Representative fluorescent in situ hybridization images of PSAP mRNA in the cingulate cortex of mice injected with AAV-GFP and AAV-GFP-Cre. Upper row, schematic depiction of stereotaxic injection sites in one hemisphere (the same in the other hemisphere). Scale bar, 50 μm. (B) Representative immunofluorescent staining images of GFP (cyan), Cre (orange), PSAP (magenta), and PGRN (yellow) in the cingulate cortex of mice injected with AAV-GFP and AAV-GFP-Cre, respectively. Scale bar, 20 μm. (C,D) Bar graphs showing quantification of mean fluorescence intensity (MFI) of PSAP (C) and PGRN (D) staining in GFP- or Cre-positive cells. A.U, arbitrary unit. Student’s t-test, N = 34 cells in each group. Data are presented as mean ± S.E.M. **** p ˂ 0.0001. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/36233357), licensed under a CC-BY license. Not internally tested by R&D Systems.